PF-05251749 is a modulator of Casein kinase 1 delta and Casein kinase 1E , which was being developed by Pfizer for the treatment of Alzheimer's disease. It is an oral compound.
In 2015, Pfizer conducted a single-site, single-ascending-dose study in 32 healthy volunteers, assessing its propensity to induce movement disorders and affect mood and fatigue, as well as pharmacokinetics and exposure in CSF.
In March 2016, the company started an ascending-multiple-dose study of 50 to 900 mg daily of this compound in 97 healthy elderly volunteers at two sites in Florida. This trial also assessed suicidality and melatonin production, and expanded the number of pharmacokinetic measures. One arm administered PF-05251749 together with melatonin.
In January 2018, Pfizer announced it was ending its neurology research and development, including this compound.
For all trials of this drug, see clinicaltrials.gov.
Last Updated: 02 Feb 2018
No Available Further Reading